PTEN and vascular malformation: With reference to the updated ISSVA classification system several disease entities involving vascular malformations had 100% partial response to Sirolimus at end of treatment at 6 months and end of treatment at 12 months in this study such as (1) GLA, (2) capillary-lymphatic venous malformation (CLVM), (3) Phosphatase and tensin homolog (PTEN)/arterial venous malformation, and (4) venous lymphatic malformation (2).